BC-DXI-843
BC-DXI-843 is inhibitor of AIMP2-DX2, and is potential for development of novel therapeutics targeting AIMP2-DX2 in lung cancer.Optimization of hit BC-DXI-04 (IC50 = 40.1 μM) provided new potent sulfonamide based AIMP2-DX2 inhibitors. Among these, BC-DXI-843 showed improved inhibition against AIMP2-DX2 (IC50 = 0.92 μM) with more than 100-fold selectivity over AIMP2 in a luciferase assay. Several binding assays indicated that this compound effectively induces cancer cell apoptosis by specifically interrupting the interaction between DX2 and HSP70, which leads to the degradation of DX2 via Siah1-mediated ubiquitination.BC-DXI-843 demonstrated in vivo efficacy in a tumor xenograft mouse model (H460 cells) at a dosage of 50 mg/kg, suggesting it as a promising lead for development of novel therapeutics targeting AIMP2-DX2 in lung cancer.
Product Specifications
CAS Number
2421117-98-6
Purity
>98% (HPLC)
Solubility
DMSO:245mg/ml (448.18 Mm; Need ultrasonic)
Smiles
COC1=CC=C (C=C1) C1=CSC (NC (=O) [C@H] (CC2=CNC3=CC=CC=C23) NS (=O) (=O) C2=CC=C (C) C=C2) =N1
Molecular Formula
C28H26N4O4S2
Molecular Weight
546.66
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Olr801 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)
